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Bruce Budowle1,2The story of Kaitlin Hunter [1] brings to light the potential
triumphs of the age of biotechnology and how an under-
standing of the interplay of genomics and the human
microbiome can provide a cure to a life-threatening
disease. After a serious car accident and under standard
healthcare, Kaitlin was given antibiotics to prevent infec-
tion. Likely, the antibiotic treatment compromised her
normal gastrointestinal flora and permitted Clostridium
difficile, a toxin-producing, Gram-positive, anaerobic,
spore-forming bacillus, to become established. C. difficile
causes diarrhea and is linked to approximately 14,000
deaths each year in the United States alone [2]. However, a
novel solution was undertaken to treat Kaitlin - her
mother, a healthy donor, provided a fecal sample which
was transplanted into Kaitlin’s colon. Her mother’s bac-
teria re-colonized the colon and Kaitlin was cured. This
life-saving treatment may make one reconsider the phrase
of ‘taking no “_ _ _ _” from anyone’.
While a fecal transplant makes logical sense for staving
off a C. difficile infection, there are patients (and physi-
cians) who may not opt for such a treatment. First,
patients may not relish the thought of receiving fecal mat-
ter that would be infused directly into their colons. The
thought of it is unpleasant at best. Second, a fecal sample
even from a healthy donor would be replete with bacteria,
some of which may be pathogenic or at least opportunistic
pathogens. However, Petrof et al. [3] have devised a solu-
tion to ‘RePOOPulate’ the intestines of patients with
C. difficile infections. They used investigative genetics
technology to develop a stool substitute, which poses less
risk to the patient, and probably for the first time
employed massively parallel sequencing (MPS) to track a
transplant and monitor a patient’s recovery. Thereby, they
demonstrated that the disruptive MPS technology has
immediate diagnostic applications.Correspondence: Bruce.Budowle@unthsc.edu
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stated.Petrof et al. obtained a stool sample from a healthy,
41-year-old woman and isolated 62 different bacteria.
After rejecting antibiotic-resistant microbes - those that
may cause disease, 33 intestinal bacteria isolates remained.
These isolates were reconstituted in proportions to ap-
proximate those from the original stool sample. Thus
Petrof at el. created a stool substitute mixture comprised
of a multispecies community no longer in the presence of
fecal material.
Two patients were selected for ‘repoopulation’. They were
a 74-year-old Caucasian woman with six episodes of re-
current C. difficile infection over an 18-month period and
a 70-year-old Caucasian woman with a history of periph-
eral neuropathy, which predisposed her to recurrent skin
and soft tissue infections and under cefazolin treatment
developed a C. difficile infection. Both were infected with
a particularly hypervirulent strain of C. difficile, ribotype
078. These patients posed a challenge because of age and
recurrent infection.
The status of pretreatment and post-treatment micro-
biota was monitored by sequencing PCR products of the
bacterial V6 rRNA region on the Ion Torrent platform
with low to medium throughput chips for the instrument.
The Ion Torrent is one of the commercially available mas-
sively parallel sequencers that enables genomic analyses
on the bench top of most laboratories which was only a
short time ago the domain of large genomic centers.
Throughput of the sequencing chips is upwards of 100
megabases and for single patient monitoring was deemed
sufficient to obtain a depth of coverage to assess diversity
of the patients’ intestinal microbial flora. Up to 12 samples
were multiplexed on each chip through use of indexing.
Therefore community microbial composition analysis
could be assessed in virtually real-time (that is, 24 to 48 h)
to track the success or failure of the stool substitute trans-
plant to re-establish the microbiota of the patients.
Sufficient V6 rRNA reads were obtained (between 3,758
and 76,752 V6 rRNA reads per sample for Patient 1 and
between 19,751 and 64,200 reads per sample for Patient 2)
to estimate general and relative diversity of the microflora. This is an Open Access article distributed under the terms of the Creative
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ment, each patient recovered a normal bowel pattern and
remained symptom-free for up to 6 months when moni-
toring was stopped. The first patient displayed a highly
diverse microbiota that after treatment became less di-
verse and after 6 months regained similar diversity as that
of pretreatment. The second patient’s microbiota had rela-
tively low diversity and became more diverse following
treatment which stabilized with a higher diversity than
that of pretreatment. Genomic analyses demonstrated
that the rRNA sequences representative of the stool
substitute were infrequent in the pretreatment stool
samples of the patients. Once stabilized, the same
sequences comprised >25% of the patients’ samples.
Taxonomic assignment with rRNA V6 region could only
be carried out at the family level as greater phylogenetic
resolution cannot be attained using a single house-keeping
gene. This lack of resolution did not compromise monitor-
ing for stool substitute transplantation success. However,
given the throughput of MPS, adding a few more house-
keeping genes could easily provide species/strain level reso-
lution and even monitor for mutation that may arise.
Although successful, the RePOOPulation study was lim-
ited to two patients and more studies are needed. How-
ever, Petrof et al. have demonstrated the proof of concept
that this stool substitute, synthetically reconstituted from
fecal material, can be an effective treatment for C. difficile
infection, particularly for recurrent infections with hyper-
virulent strains. The authors point out that there are
several advantages to using a substitute over actual fecal
material, besides the obvious distaste of having such
material injected into one’s body. These include ‘the exact
composition of bacteria administered is known and can be
controlled; the bacterial species composition can be repro-
duced, should a future treatment be necessary; prepara-
tions of pure culture are more stable than stool, which
some groups recommend should be collected fresh and
instilled into the recipient within 6 h of collection; an ab-
sence of viruses and other pathogens in the administered
mixture can be ensured, thereby improving patient safety;
and the administered organisms can be selected based on
their sensitivity to antimicrobials, allowing an enhanced
safety profile’.
It is hard to believe that only a few years ago the human
microbiome was defined solely by E. coli and bacteria that
caused bad breath and tooth decay. The diversity of the
human microbiome is substantial and its secrets, as they
unravel, promise to bring additional insights to human
health and potential treatments to improve well-being. In-
vestigative genetics tools, such as high throughput sequen-
cing and targeted gene diagnostics, will figure prominently
into our personalized medical treatment and fecal, or
simulate, transplantation is just the tip of the iceberg.
Who knows… the next time one of us travels to an area ofthe world where the microflora of the water can cause
intestinal discomfort, a possible pretreatment for better
well-being during travel may be a stool simulant enema.
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